Poseltinib

Poseltinib
Clinical data
Other names	HM-7122; LY 3337641
Identifiers
	IUPAC name N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide;
CAS Number	1353552-97-2;
PubChem CID	56644522;
UNII	D01E4B1U35;
CompTox Dashboard (EPA)	DTXSID501112972 ;
Chemical and physical data
Formula	C26H26N6O3
Molar mass	470.533 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1;
	InChI InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30); Key:LZMJNVRJMFMYQS-UHFFFAOYSA-N;

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis.^[1] It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.^[2]

Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.^[3]

References

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.